Get the Stockscreener App
123.24
3.61%
-4.61
After Hours:
123.24
Repligen Corp stock is traded at $123.24, with a volume of 580.99K.
It is down -3.61% in the last 24 hours and down -0.49% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$127.85
Open:
$128.36
24h Volume:
580.99K
Relative Volume:
0.75
Market Cap:
$7.95B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-397.55
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-12.91%
1M Performance:
-0.49%
6M Performance:
-12.41%
1Y Performance:
-25.26%
1-Day Range:
$123.10
$130.87
1-Week Range:
$123.10
$143.56
52-Week Range:
$102.97
$182.52
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
123.24 | 7.95B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Things To Consider Before Buying Repligen Corp (NASDAQ: RGEN) - Stocksregister
Global Hollow Fiber Filtration Market Set to Witness - openPR.com
Investor’s Toolkit: Key Ratios for Assessing Repligen Corp (RGEN)’s Performance - DWinneX
Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright - Defense World
Repligen (RGEN) Maintains Buy Rating with $180 Price Target | RG - GuruFocus
FY2025 EPS Estimates for Repligen Boosted by William Blair - Defense World
Leerink Partnrs Has Pessimistic View of Repligen Q2 Earnings - Defense World
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare - Insider Monkey
There is no doubt that Repligen Corp (RGEN) ticks all the boxes. - Sete News
Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’ - Insider Monkey
Wolfe Research Upgrades Repligen (NASDAQ:RGEN) to “Outperform” - Defense World
BlackRock, Inc. Reduces Stake in Repligen Corp: An In-Depth Anal - GuruFocus
Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings) - Benzinga
Wolfe Research Upgrades Repligen Corp (RGEN) to an Outperform from a Peer perform - knoxdaily.com
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty - Yahoo Finance
Repligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock News - GuruFocus
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Repligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Repligen: Q1 Earnings Snapshot - CT Insider
Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Re - GuruFocus
JPMorgan cuts Repligen stock price target to $190, maintains rating By Investing.com - Investing.com South Africa
Earnings call transcript: Repligen Q1 2025 earnings beat expectations - Investing.com
Jefferies cuts Repligen target to $914, maintains Buy rating - Investing.com
Truist cuts Repligen target to $940, maintains Buy rating - Investing.com
JPMorgan cuts Repligen stock price target to $190, maintains rating - Investing.com
Repligen (RGEN) Target Price Adjusted to $190 by JPMorgan | RGEN Stock News - GuruFocus
Repligen (RGEN) Receives Upgrade from Wolfe Research Following E - GuruFocus
Repligen Corp (NASDAQ: RGEN) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Repligen (RGEN) Achieves Strong Revenue Growth in Q1 | RGEN Stock News - GuruFocus
Repligen Corp’s Market Journey: Closing Weak at 143.63, Down -0.77 - DWinneX
Repligen earnings beat by $0.04, revenue topped estimates - Investing.com
RGEN’s valuation metrics: A comprehensive analysis - uspostnews.com
Repligen Corp Q1 2025 Earnings: Revenue Surpasses Estimates at $169 Million, Adjusted EPS Soars to $0.39 - GuruFocus
What To Expect From Repligen Corp (RGEN) Q1 2025 Earnings - GuruFocus
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations - Yahoo
Repligen Corporation Q1 2025 Financial Results - TradingView
Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com - Defense World
Repligen (RGEN) Q1 Earnings: What To Expect - Yahoo Finance
Repligen (RGEN) Projected to Post Earnings on Tuesday - Defense World
Investor’s Delight: Repligen Corp (RGEN) Closes Strong at 141.40, Up 1.78 - DWinneX
A year in review: Repligen Corp (RGEN)’s performance in the last year - uspostnews.com
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Repligen Corp (NASDAQ: RGEN) Shares Have Loss -0.78% Over The Past Month - Marketing Sentinel
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Repligen Co. (NASDAQ:RGEN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.40%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):